These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14985917)

  • 1. MDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press.
    Green AR
    Psychopharmacology (Berl); 2004 May; 173(3-4):231-3. PubMed ID: 14985917
    [No Abstract]   [Full Text] [Related]  

  • 2. The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
    Parrott AC; Rodgers J; Buchanan T; Scholey AB; Heffernan T; Ling J
    Psychopharmacology (Berl); 2004 Jan; 171(2):231-3. PubMed ID: 14634710
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
    Sumnall HR; Jerome L; Doblin R; Mithoefer MC
    Psychopharmacology (Berl); 2004 Jan; 171(2):229-30. PubMed ID: 14634709
    [No Abstract]   [Full Text] [Related]  

  • 4. Modelling the adverse effects associated with ecstasy use.
    Fisk JE; Murphy PN; Montgomery C; Hadjiefthyvoulou F
    Addiction; 2011 Apr; 106(4):798-805. PubMed ID: 21182557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of cannabis and MDMA ("ecstasy") to cognitive changes in long-term polydrug users.
    Dafters RI; Hoshi R; Talbot AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):405-10. PubMed ID: 12955295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Paramethoxymethamphetamine].
    Westin AA; Brede WR
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2008. PubMed ID: 22016127
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 8. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of MDMA (ecstasy), and multiple drugs use on (simulated) driving performance and traffic safety.
    Brookhuis KA; de Waard D; Samyn N
    Psychopharmacology (Berl); 2004 May; 173(3-4):440-5. PubMed ID: 14714102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylene 3, 4 dioxymethamphetamine-induced acute myocardial infarction.
    Lai TI; Hwang JJ; Fang CC; Chen WJ
    Ann Emerg Med; 2003 Dec; 42(6):759-62. PubMed ID: 14634599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Has ecstasy neurotoxic effects in humans?].
    Rosenberg R
    Ugeskr Laeger; 1999 Dec; 161(50):6941. PubMed ID: 10643384
    [No Abstract]   [Full Text] [Related]  

  • 12. Ecstasy (MDMA) and memory function: a meta-analytic update.
    Laws KR; Kokkalis J
    Hum Psychopharmacol; 2007 Aug; 22(6):381-8. PubMed ID: 17621368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a case for MDMA-assisted psychotherapy in the UK?
    Sessa B
    J Psychopharmacol; 2007 Mar; 21(2):220-4. PubMed ID: 17329304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 15. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy').
    Montastruc F; Montastruc G; Vigreux P; Bruneval P; Guilbeau-Frugier C; Cron C; Bagheri H; Delisle B; Lapeyre-Mestre M; Pathak A; Montastruc JL
    Br J Clin Pharmacol; 2012 Sep; 74(3):547-8. PubMed ID: 22364182
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective neurocognitive deficits associated with multiple doses of ecstasy/MDMA: a reply to Cole.
    Fox HC; Parrott AC
    J Psychopharmacol; 2003 Jun; 17(2):242-4. PubMed ID: 12870575
    [No Abstract]   [Full Text] [Related]  

  • 17. The dark side of ecstasy: neuropsychiatric symptoms after exposure to 3,4-methylenedioxymethamphetamine.
    Karlsen SN; Spigset O; Slørdal L
    Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):15-24. PubMed ID: 18047478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecstasy ingestion and fulminant hepatic failure: liver transplantation to be considered as a last therapeutic option.
    Garbino J; Henry JA; Mentha G; Romand JA
    Vet Hum Toxicol; 2001 Apr; 43(2):99-102. PubMed ID: 11308131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The agony and the ecstasy: acute urinary retention after MDMA abuse.
    Inman DS; Greene D
    BJU Int; 2003 Jan; 91(1):123. PubMed ID: 12614266
    [No Abstract]   [Full Text] [Related]  

  • 20. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
    Daumann J; Hensen G; Thimm B; Rezk M; Till B; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2004 May; 173(3-4):398-404. PubMed ID: 14722704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.